Legal Implications of Peptide Use in Sports

"Research Chemical" vs. "Banned Substance"

A peptide sold online as a "research chemical, not for human consumption" falls under two separate sets of rules. Drug regulators such as the FDA decide whether a product can be marketed and sold. The World Anti-Doping Agency (WADA) decides what an athlete in a tested sport may have in their body. A peptide can be easy to buy and still be prohibited at all times in sport.

The purchase side is also less settled than older guides suggest. As of October 2026, FDA warning letters say a "research use only" label doesn't protect a seller whose marketing points to human use. In an August 24, 2026 letter to a Texas seller whose products included PT-141 and tesamorelin, FDA wrote that despite labels such as "not for human or veterinary use," the seller's website showed the products were intended as drugs for human use. It cited drug claims on product pages and the sale of bacteriostatic water for reconstituting the vials. Purchase and import rules also differ by country; our page on peptide legal status in different countries covers that side.

Where Peptides Sit on the Prohibited List

WADA's 2026 Prohibited List has been in force since January 1, 2026. It's the version that applies as of October 2026. Most performance peptides are named in either S2 or S0. Both sections apply in and out of competition, so for a tested athlete the section matters less than the fact of being listed.

S2: Peptide Hormones and Growth Factors

Section S2.2.4 covers growth hormone releasing factors, and the 2026 List names the common ones directly:

• GHRH analogues: CJC-1293, CJC-1295, sermorelin and tesamorelin.
• GH secretagogues and mimetics: including ipamorelin, ibutamoren (MK-677), anamorelin and lenomorelin (ghrelin).
• GH-releasing peptides (GHRPs): GHRP-1 through GHRP-6, alexamorelin and examorelin (hexarelin).

The GH fragments AOD-9604 and hGH 176-191 are named in S2.2.3. S2.3, the growth factor section, covers IGF-1 analogues such as IGF-1 LR3. It also lists mechano growth factors and "Thymosin-β4 and its derivatives e.g. TB-500." These entries say "including, but not limited to," so a compound with the same action is covered even when its name isn't printed.

S0: Non-Approved Substances

S0 is the catch-all. The 2026 List prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." It names BPC-157 as an example. Because S0 only applies to substances that no other section addresses, TB-500 sits in S2.3 rather than S0, even though neither peptide is approved anywhere.

The 2027 List takes effect on January 1, 2027. According to USADA's athlete advisory, it names "peptides" in general as prohibited substances in S0. USADA also warns that its GlobalDRO lookup tool doesn't list every prohibited peptide, partly because some are sold under other names.

Common Peptides on the 2026 List

Melanocortins: Melanotan II and PT-141

S2 names no melanocortin peptides, so tables that list melanotan II or PT-141 under S2 are wrong. Melanotan II isn't named anywhere on the List, and we found no regulatory approval for it, which would put it under S0 by the definition above. That's our reading, not a WADA ruling.

PT-141 is a different case. Bremelanotide has been FDA-approved since 2019 as Vyleesi, a prescription medicine for premenopausal women with acquired, generalized hypoactive sexual desire disorder. With a current approval, the S0 definition doesn't clearly apply, and no other section names it. As of October 2026, we couldn't find a WADA or USADA statement on bremelanotide, so its status for tested athletes is unverified. A vial sold as research-use "PT-141" also isn't the approved medicine: FDA's August 2026 letters treat those vials as unapproved new drugs.

What Anti-Doping Labs Can Detect

Detection has two parts: whether a validated test exists for a peptide, and how long after use it can still find it. The published record answers the first far better than the second.

Tests for the Peptide Itself

Anti-doping labs mostly rely on liquid chromatography coupled with mass spectrometry (LC-MS), which separates a urine or blood sample and identifies a peptide by its mass and the way it breaks apart. Published methods cover most of the peptides on this site:

• GHRPs and secretagogues. In 2011 the Cologne anti-doping lab published a urine method covering eight GHRPs, noting that the established test for growth hormone itself misses these compounds. A 2016 method from the same group screens urine directly for 18 small prohibited peptides (TB-500 and AOD-9604 among them), with detection limits of 50-500 pg/mL.
• BPC-157. In 2017 the Sports Medicine Research and Testing Laboratory in Salt Lake City identified BPC-157 in confiscated vials and validated a urine method with a detection limit of 0.1 ng/mL. In lab experiments the peptide formed a stable metabolite, and measuring that metabolite alongside the parent peptide made the test more specific.
• TB-500. In 2012 the Ghent anti-doping lab identified the fragment in TB-500 products (Ac-LKKTETQ, a seven-amino-acid piece of thymosin beta-4) and proposed a strategy for finding it in plasma and urine.
• Dried blood spots. A 2026 Ghent method detects 54 prohibited compounds in dried blood spots; BPC-157 and TB-500 are on its list. The compounds stayed detectable in dried samples throughout the storage study, which simplifies shipping.

We couldn't find public data on how often labs include these peptides in routine screening, so the existence of a method says little about how often a given peptide is actually tested for.

Detection Windows

This is where the evidence is thinnest. The human excretion data come from very small studies:

• In a 2015 study from the Moscow anti-doping center, one volunteer per compound took a GHRP as a nasal spray. GHRP-2 and its metabolites were found in urine up to 47 hours later, and unchanged GHRP-6 up to 23 hours. The authors concluded that the window varies with each person's metabolism and with the product and route used.
• In the 2011 Cologne study, a GHRP-2 metabolite was detectable for more than 20 hours after a single 10 mg oral dose, while the intact drug wasn't found at all.

For BPC-157 and TB-500, we found no published human excretion study, so their detection windows in people are unknown as of October 2026. The 2017 BPC-157 paper showed the peptide stayed stable in stored urine for at least four days, but that's about sample handling, not how long it remains detectable after use.

The Athlete Biological Passport

The Athlete Biological Passport (ABP) tracks an athlete's own markers over time instead of looking for a specific drug. According to WADA, an Endocrine Module was added in 2023, aimed at growth hormone and substances that raise it (releasing factors and IGF-1).

A 2022 study led by WADA scientists tested this approach with IGF-1 and P-III-NP, a collagen-turnover marker. At a 99% specificity setting it flagged 20 of 27 people given recombinant growth hormone, 17 of them after they had stopped. That study used growth hormone itself. We found no published data on how well the passport picks up secretagogues such as ipamorelin or CJC-1295, so its value against those peptides is an expectation, not a measured result.

Strict Liability

The World Anti-Doping Code makes athletes responsible for any prohibited substance or its metabolites found in their sample. Under Article 2.1, a violation doesn't require proof that the athlete meant to use the substance or was at fault. Fault and intent come into play when the length of the sanction is decided. Our guide to the Prohibited List for tested athletes covers strict liability and contaminated-product claims in more detail.

What We Still Don't Know

The biggest gap is detection windows. Methods exist for BPC-157 and TB-500, but without human excretion studies nobody can say how long either stays detectable after use, and the GHRP data rest on single volunteers.

PT-141's status is unverified now that bremelanotide is an approved medicine. The same question applies to elamipretide (SS-31), which received FDA accelerated approval as Forzinity for Barth syndrome in September 2025. It's also unclear how anti-doping bodies will apply the 2027 List's general reference to peptides in S0.

On the purchase side, FDA's decisions on whether pharmacies may compound peptides such as BPC-157 and TB-500 were still open as of October 2026. A change there wouldn't alter anything on the Prohibited List. Our timeline of regulatory changes affecting peptides in sport tracks both sides.